144 completed, 35 unknown, 22 terminated, 18 recruiting. 239 Phase 3, 53 Phase 2.
Follow Atherosclerosis: new trials by email Literature Review of Atherosclerosis trials Research Report on Atherosclerosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The NICE-PAD II Trial Nicotinamide Riboside (NR), Placebo - Peripheral Artery Disease (PAD) | Phase 3 | Not yet recruiting | Northwestern University | 250 | 2026-12-01 | 2026-08-24 |
| Nicorandil in Atherosclerosis Risk in Patients With Rheumatoid Arthritis Nicorandil 10 MG Oral scored Tablet, DMARD maintenance - Rheumatoid Arthritis (RA, Atherosclerosis | Phase 3 | Not yet recruiting | Tanta University | 46 | 2026-09-01 | 2026-09-11 |
| Reducing Adverse Vascular Outcomes With Factor XI Inhibition in Adult Participants With Peripheral Artery Disease REGN7508, REGN9933, Placebo - Peripheral Artery Disease (PAD) | Phase 3 | Recruiting | Regeneron Pharmaceuticals | 7050 | 2026-07-10 | 2026-11-05 |
| Colchicine in Chronic Limb-Threatening Ischemia Colchicine 0.5 MG Oral Tablet Once Daily, Placebo - Chronic Limb-Threatening Ischemia | Phase 3 | Recruiting | Shin Kong Wu Ho-Su Memorial Hospital | 200 | 2026-06-02 | 2026-07-14 |
| Evaluating Bu Yang Huanwu Decoction For Early Diabetic Vascular Disease Hua Yu Wan Capsule, Aspirin - Peripheral Arterial Disease, Diabetic Angiopathies | Phase 3 | Not yet recruiting | Xuanwu Hospital, Beijing | 300 | 2026-06-01 | 2026-06-22 |
| A Study to See if Lepodisiran Can Reduce Plaque in Coronary Arteries of Adults With Elevated Lp(a) Who Have Had Heart Events or Are at High Risk Lepodisiran, Placebo - Atherosclerosis, Cardiovascular Diseases | Phase 3 | Recruiting | Eli Lilly and Company | 252 | 2026-06-01 | 2026-11-04 |
| A Phase III Study To Evaluate the Efficacy And Safety Of HRS9531 In Participants With Atherosclerotic Cardiovascular Disease HRS9531, HRS9531 placebo - Atherosclerotic Cardiovascular Disease | Phase 3 | Recruiting | Fujian Shengdi Pharmaceutical Co., Ltd. | 9262 | 2026-05-29 | 2026-09-08 |
| A Study Comparing the MAGICTouch™ Sirolimus-coated Balloon With a Paclitaxel-coated Balloon for Treating Severe Narrowing or Blockage in the Femoropopliteal Arteries. Sirolimus (RAPAMUNE) drug-coated balloon angioplasty catheter, Paclitaxel drug-coated balloon angioplasty - Popliteal Artery Disease, Superficial Femoral Artery Disease | Phase 2 / Phase 3 | Not yet recruiting | Concept Medical Inc. | 478 | 2026-04-01 | 2026-04-17 |
| Effects of Ziltivekimab on Coronary Atherosclerotic Burden in Patients With Acute Myocardial Infarction Ziltivekimab, Placebo - Coronary Artery Disease, Acute Myocardial Infarction (AMI) | Phase 3 | Recruiting | ECRI bv | 332 | 2025-12-19 | 2026-03-23 |
| Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease Orforglipron, Placebo - Peripheral Arterial Disease | Phase 3 | Recruiting | Eli Lilly and Company | 1205 | 2025-10-31 | 2026-11-04 |
| Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a) Muvalaplin, Placebo - Elevated Lp(a), Atherosclerotic Cardiovascular Disease (ASCVD) | Phase 3 | Recruiting | Eli Lilly and Company | 10450 | 2025-09-02 | 2026-09-24 |
| Improving Mobility After Revascularization in Peripheral Artery Disease Home Based Exercise, Nitrate Rich Beetroot Juice, Attention Control - Peripheral Artery Disease, Intermittent Claudication | Phase 3 | Recruiting | Northwestern University | 386 | 2025-08-04 | 2026-10-05 |
| Temsirolimus Adventitial Delivery to Improve ANGioplasty and/or Atherectomy Revascularization Outcomes Below the Knee Temsirolimus, Saline placebo - Peripheral Artery Disease, Critical Limb Ischemia | Phase 3 | Recruiting | Mercator MedSystems, Inc. | 250 | 2025-07-30 | 2025-08-05 |
| Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity Maridebart Cafraglutide, Placebo - Atherosclerotic Cardiovascular Disease, Overweight | Phase 3 | Active not recruiting | Amgen | 12800 | 2025-07-25 | 2026-10-29 |
| Polypill and Colchicine for Risk Reduction in Atherosclerotic Cardiovascular Disease Cardiovascular Polypill (Valsartan, Atorvastatin, Aspirin), Colchicine 0.5 mg, Usual Care Group - Atherothrombotic Diseases, Atherosclerotic Cardiovascular Disease (ASCVD) | Phase 3 | Recruiting | Hospital do Coracao | 7713 | 2025-06-12 | 2026-01-22 |
| A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First Event AZD0780, Placebo - Cardiovascular Disease | Phase 3 | Recruiting | AstraZeneca | 15100 | 2025-06-04 | 2026-08-24 |
| A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With Clinical ASCVD or at Risk for a First ASCVD Event AZD0780, Placebo - Cardiovascular Disease | Phase 3 | Active not recruiting | AstraZeneca | 3103 | 2025-05-28 | 2026-08-11 |
| Pelacarsen Roll-over Extension Program Pelacarsen (TQJ230) - Atherosclerotic Cardiovascular Disease | Phase 3 | Active not recruiting | Novartis Pharmaceuticals | 599 | 2025-05-19 | 2026-10-14 |
| Lp(a) Lowering Study of Pelacarsen (TQJ230) With Background Inclisiran in Participants With Elevated Lp(a) and Established ASCVD Pelacarsen, Placebo, Inclisiran - Atherosclerotic Cardiovascular Disease (ASCVD) | Phase 3 | Active not recruiting | Novartis Pharmaceuticals | 246 | 2025-04-30 | 2026-10-14 |
| The Prevent Coronary Artery Disease Trial Inclisiran - Atherosclerotic Cardiovascular Disease | Phase 3 | Recruiting | Icahn School of Medicine at Mount Sinai | 1600 | 2024-09-12 | 2025-04-29 |
Showing 20 of 239. Sign in to see all of them.
Peripheral Arterial Disease (88) · Cardiovascular Diseases (31) · Peripheral Vascular Diseases (30) · Chronic Limb-Threatening Ischemia (28) · Hypercholesterolemia (23) · Coronary Artery Disease (20) · Diabetes Mellitus (18) · Intermittent Claudication (15) · Coronary Disease (14) · Myocardial Infarction (14) · Inflammation (12) · Stroke (12) · Diabetes Mellitus, Type 2 (10) · Heart Diseases (10)
Arteriosclerosis (239) · Vascular Diseases (236) · Arterial Occlusive Diseases (230) · Cardiovascular Diseases (208) · Pathological Conditions, Signs and Symptoms (87) · Peripheral Vascular Diseases (81) · Pathologic Processes (64) · Nutritional and Metabolic Diseases (57) · Metabolic Diseases (55) · Myocardial Ischemia (42) · Heart Diseases (40) · Ischemia (40) · Lipid Metabolism Disorders (31) · Chronic Disease (30)
Aspirin (12) · Atorvastatin (11) · Clopidogrel (11) · Ezetimibe (10) · ALN-PCS (7) · Simvastatin (7) · 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid (6) · Rosuvastatin Calcium (6) · Colchicine (5) · Ticagrelor (5) · Angioplasty (4) · Ezetimibe, Simvastatin Drug Combination (4) · Niacin (4) · Rivaroxaban (4) · Rosiglitazone (4)
Novartis Pharmaceuticals (8) · Northwestern University (7) · AstraZeneca (6) · Esperion Therapeutics, Inc. (6) · National Heart, Lung, and Blood Institute (NHLBI) (6) · Eli Lilly and Company (5) · Flanders Medical Research Program (5) · Boston Scientific Corporation (4) · Brigham and Women's Hospital (4) · Merck Sharp & Dohme LLC (4) · Organon and Co (4) · UMC Utrecht (4) · Assistance Publique - Hôpitaux de Paris (3) · Bayer (3) · Beijing Northland Biotech. Co., Ltd. (3)
United States (106) · Canada (44) · Netherlands (39) · Germany (38) · United Kingdom (34) · China (32) · France (31) · Poland (30) · Brazil (28) · Czechia (28) · Hungary (28) · Italy (28) · Spain (28) · Belgium (25) · Japan (25)
Howard N. Hodis, MD (5) · Ron Haberman, MD (5) · Marc Bosiers, MD (4) · Andrew Selwyn, MD (2) · Danielle Duffy, MD (2) · Gilbert Wagener, MD (2) · Louise Bowman (2) · Manish Mehta, MD, MPH (2) · Marc Ditmarsch, MD (2) · Martin Landray (2)
PMID 42573020, PMID 32609313, PMID 35916348, PMID 42035974, PMID 37565307, PMID 27902833, PMID 28382371, PMID 28988157, PMID 29632238, PMID 35196863, PMID 35224730, PMID 36588397, PMID 38551015, PMID 39329200, PMID 41329869, PMID 10650308, PMID 11239408, PMID 11730394, PMID 12234947, PMID 12628952, PMID 12850465, PMID 1342820, PMID 15389223, PMID 16722590, PMID 17026909, PMID 17050890, PMID 17299195, PMID 17329508, PMID 17548727, PMID 17617342, PMID 17634457, PMID 18289548, PMID 18376000, PMID 18378631, PMID 18422390, PMID 18502300, PMID 18506009, PMID 18519471, PMID 18539917, PMID 18612130, PMID 18673542, PMID 18762502, PMID 18774745, PMID 18784409, PMID 19118243, PMID 19158205, PMID 19293413, PMID 19303966, PMID 19331677, PMID 19364991
2025 (6), 2014 (2), 2016 (2), 2017 (2), 2023 (2), 2015 (1), 2019 (1), I01CX002150 (1), N01AR022265 (1), N01HC95178 (1), N01HC95179 (1), N01HC95180 (1), N01HC95181 (1), N01HC95182 (1), N01HC95183 (1)